Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemastine fumarate for cognitive function and prognosis after ruptured intracranial aneurysm
ChiCTR2500109656Phase 3Not yet recruiting
- Sponsor
- Nanjing Medical University Affiliated Wuxi Second Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in subarachnoid hemorrhage (SAH) comparing Placebo group with Drug intervention group (clemastine fumarate) (2 arms). Primary endpoints: Glasgow Outcome Scale-Extended (GOS-E) and Disability Rating Scale (DRS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
clemastine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on ChiCTR2500109656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109656.